UBS Group’s Kinnate Biopharma Inc. Common Stock KNTE Stock Holding History

UBS Group’s Portfolio KNTE Stock Details KNTE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-818	Closed	-$2.18K	–	10455
2024 Q1	$2.18K	Sell	818 -4,273	-84%	-$10.6K	﹤0.01%	7966
2023 Q4	$12.1K	Buy	+5,091	New	+$9.01K	﹤0.01%	7366
2021 Q4	–	Sell	-730	Closed	-$17K	–	10907
2021 Q3	$17K	Buy	730 +478	+190%	+$10.4K	﹤0.01%	7366
2021 Q2	$6K	Sell	252 -536	-68%	-$13.6K	﹤0.01%	8475
2021 Q1	$25K	Sell	788 -39,165	-98%	-$1.36M	﹤0.01%	7186
2020 Q4	$1.59M	Buy	+39,953	New	+$1.6M	﹤0.01%	3607

UBS Group's KNTE Position: Q2 2024 in Review

UBS Group sold out of Kinnate Biopharma Inc. Common Stock (KNTE) in Q2 2024, closing a stake of 818 shares — an estimated $2.18K sold.

UBS Group first reported a position in KNTE in Q4 2020 and held it in 6 quarters. The position peaked at $1.59M in Q4 2020. 0 funds tracked by Wall St. Rank hold KNTE as of Q2 2024.

UBS Group reported no remaining Kinnate Biopharma Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
UBS Group sold 818 Kinnate Biopharma Inc. Common Stock shares in Q2 2024, an estimated $2.18K.
UBS Group first reported a position in Kinnate Biopharma Inc. Common Stock in Q4 2020 and held it in 6 quarters.
UBS Group's Kinnate Biopharma Inc. Common Stock position peaked at $1.59M in Q4 2020.
0 funds tracked by Wall St. Rank held Kinnate Biopharma Inc. Common Stock as of Q2 2024.

Based on UBS Group's 13F filing for Q2 2024, filed 14 Aug 2024.